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Cyclosporin A (CSA) is an immunosuppressor used in
organ transplantation. A recent proteomic analysis has
revealed that activation of T cells in the presence of CSA
induces the synthesis of hundreds of new proteins. Here
we used representational difference analysis to charac-
terize some of the corresponding induced genes. After
cDNA bank screening we focused on one of these genes,
which we named CSA-conditional, T cell activation-de-
pendent (CSTAD) gene. This gene produces two mRNAs
resulting from alternative splicing events. They encode
two proteins of 104 and 141 amino acids, CSTADp-S and
CSTADp-L, for the short and long forms, respectively.
FK506 had the same effect as CSA, whereas rapamycin
did not affect the level of CSTAD gene expression, dem-
onstrating that inhibition of the calcineurin activation
pathway is involved in CSTAD gene up-regulation. CSA
also led to overexpression of CSTAD in mice immunized
in the presence of CSA, confirming the in vitro analysis.
Microscopic and cytofluorimetric analysis of cells ex-
pressing green fluorescent protein-tagged CSTADp-L
and CSTADp-S showed that both proteins colocalize
with mitochondrial markers and depolarize the mito-
chondrial transmembrane potential without causing
release of cytochrome c, apoptosis, or necrosis. Both
CSTADp isoforms are sensitive to proteinase K, imply-
ing that they are located in the mitochondrial outer
membrane. These data reveal a new mechanism of ac-
tion for CSA, which involves up-regulation of a gene
whose products are sorted to mitochondria and depolar-
ize the mitochondrial membrane.
T cell activation and proliferation result in a large reshuf-
fling of the gene transcription program; many genes become
activated, whereas others are silenced (1). This process is
highly coordinated to ensure the acquisition of optimal effector
functions and cell survival (2). Genes encoding different proto-
oncogenes are induced immediately, whereas genes encoding
cell growth and differentiation factors are induced later; fi-
nally, genes involved in cell division are transcribed at even
later times. T cell proliferation can be prevented by immuno-
suppressive drugs such as cyclosporin A (CSA),1 a molecule
successfully used in clinics to prevent graft rejection. CSA
interferes with T cell proliferation by blocking the transcription
of a set of genes encoding growth and differentiation factors (for
review, see Refs. 2 and 3). The transcription of these genes is
regulated by a Ca2-dependent pathway involving the activa-
tion of calcineurin. This serine phosphatase stimulates dephos-
phorylation of the nuclear factor of activated T cells (NFAT) (4).
Dephosphorylated NFAT migrates to the nucleus where in
conjunction with AP-1 it activates IL-2 gene transcription (5).
CSA binds to various members of the cyclophilin protein family
and forms a complex with calcineurin, preventing its activa-
tion. Thus dephosphorylation of NFAT is prevented, IL-2 is not
produced, and T cells do not proliferate (6, 7). However, other
biochemical pathways such as the Ras/Raf pathway responsi-
ble for AP-1 formation are not affected by CSA (8, 9). Finally,
the stability of AP-1, a factor expressed transiently during
activation, is increased in T cells activated in the presence of
CSA (10).
CSA therapy does not induce tolerance toward graft anti-
gens, and discontinuation of therapy is associated with graft
loss due to rejection. Thus, patients need to be treated with the
immunosuppressor during their entire life span. Deleterious
effects such as nephrotoxicity, hypertension, symptomatic hy-
per uricemy, and hyperlipidemia are associated with this treat-
ment. More damaging, CSA-treated patients display an in-
creased incidence of lympho-proliferative disorders and skin
cancers, a common and dreaded complication (11, 12). Different
reports suggest that therapy with immunosuppressors can spe-
cifically stimulate the transcription of genes that may contrib-
ute to the onset of complications arising from therapy. In par-
* This work was supported by funds from the Institut Pasteur and the
CNRS (URA 1961). The costs of publication of this article were defrayed
in part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b Present address: Unite´ de Biologie des Re´gulations Immunitaires,
INSERM Unite´ 0352, Institute Pasteur, Paris 75724 cedex 15, France.
c Both authors made equal contributions to this work.
e Supported by grants from the Fondation pour la Recherche Me´dicale
and the Association pour la Recherche sur le Cancer.
g Supported by the Ligue Contre le Cancer.
i Supported by the Fondation pour la Recherche Me´dicale, Universite´
Paris 7 and National Institutes of Health Grant R01 AI054624.
j To whom correspondence may be addressed: Laboratoire
D’activation Cellulaire et Transduction des Signaux, IBBMC, CNRS-
UMR 8619, Universite´ Paris XI, 91405 Orsay cedex, France. E-mail:
Jean.Kanellopoulos@ibbmc.u-psud.fr.
k To whom correspondence may be addressed: Institut Pasteur, 25
rue du Dr. Roux, 75724 Paris cedex 15, France. E-mail: ptbachi@
pasteur.fr.
1 The abbreviations used are: CSA, cyclosporin A; CSTAD, CSA con-
ditional, T cell activation-dependent gene; NFAT, nuclear factor of
activated T cells; RDA, representational differences analysis; EDG-1,
sphingosine 1-phosphate receptor; GFP, green fluorescence protein;
ConA, concanavalin A; IL, interleukin; RT, reverse transcription;
VDAC, voltage-dependent anion channel.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 11, Issue of March 12, pp. 10556–10563, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org10556
 at U
niv of the Pacific on A
pril 17, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ticular, CSA increases transcription of the transforming
growth factor  gene, suggesting that CSA may induce tumors
in part due to overexpression of this immunosuppressive cyto-
kine (13, 14). The finding that CSA up-regulates gene expres-
sion in cells from different tissues irrespective of their activa-
tion state suggests that calcineurin may be the ubiquitous
target, which could then affect gene expression either nega-
tively or positively.
The effects of CSA on gene up-regulation were extended
recently by a proteomic analysis of newly synthesized proteins
in T cells activated in the absence or presence of CSA (15).
Remarkably, more than 100 proteins that are not found in
resting or activated T cells were induced when stimulation was
carried out in the presence of CSA. To identify the correspond-
ing genes, we have now performed representational difference
analyses (RDA) under the same conditions. Among the up-
regulated genes we have identified a gene that we have named
CSTAD, for CSA-conditional, T cell activation-dependent gene.
CSTAD encodes two proteins of 104 and 141 amino acids that
are localized in mitochondria. Although overexpression of the
short isoform perturbs mitochondrial morphology and depolar-
izes the inner mitochondrial membrane, cytochrome c was not
released, and cells did not undergo apoptosis nor necrosis.
Finally, CSTAD up-regulation is also observed in mice immu-
nized in the presence of CSA, suggesting that the phenomenon
of CSA-induced gene up-regulation may be implicated in some
of the deleterious effects of CSA treatment.
MATERIALS AND METHODS
Mice and Immunization—Five- to eight-week-old C57BL/6 female
mice were obtained from IFFA-CREDO (L’Arbresle, France). Six- to
eight-week-old female mice expressing a transgenic T cell receptor
(V3J1.2 and V11J84) specific for the 88–104 peptide of pigeon
cytochrome c-major histocompatibility complex II I-Ek complex (16)
were bred at the Centre de Distribution, Typage & Archivage animal
(Orle´ans, France).
Reagents—The synthetic peptide (Neosystem, Strasbourg, France)
was dissolved in balanced salt solution (5 mg/ml) and kept at 80 °C.
Tetramethylrhodamine ethyl ester and MitoTracker Orange (CMXRos)
were obtained from Molecular Probes (Eugene, OR). The mouse mono-
clonal anti-cytochrome c antibody (clone 7H8.2C12) was from Pharm-
ingen. The antibody against HSP-60 was a gift from Dr. S. Susin. Texas
Red-coupled anti-mouse IgG1 antibody was from Southern Biotechnol-
ogy (Birmingham, AL). For cell culture experiments, CSA, kindly sup-
plied by Novartis France, was dissolved in absolute ethanol. FK506 was
a gift from Fujisawa Healthcare Inc. (Deerfield, IL). Rapamycin and
DABCO (1,4-diazabicyclo(2.2.2.)octane) were purchased from Sigma.
For immunizations, CSA was mixed in olive oil (10 mg/ml) and kept at
room temperature. CSA (2 mg) was administered intraperitoneally 1
day before and concomitantly with peptide injection (150 g intrave-
nously in the tail). A control group of mice received the peptide alone,
and another group received olive oil alone.
T Cell Activation—T cells were purified as previously described (10).
Briefly, spleen cells (4  108/ml) were incubated with 75 g of wheat
germ agglutinin for 10 min and loaded on top of a tube containing 8 ml
of balanced salt solution containing 50% fetal calf serum. Twenty min-
utes later non-agglutinated T cells were recovered from the top of the
tube, centrifuged, and incubated with 0.2 M N-acetyl-D-glucosamine
(Sigma) for 5 min to remove excess WGA. After 2 washes, the purity of
the T cells was analyzed by fluorescence-activated cell sorter (90–95%
of the recovered cells were CD3). The T cell-enriched fraction responds
to ConA-stimulation similarly to the unfractionated cells. Cells were
cultured in 2 ml (2  106 cells/ml) in complete RPMI (RPMI 1640,
Invitrogen) supplemented with 2 mM L-glutamine, 50 g/ml streptomy-
cin, 50 units/ml penicillin, 5% heat-inactivated fetal calf serum, 5 
105 M 2-mercaptoethanol. Two g/ml ConA (Sigma) were added at the
beginning of the culture. CSA (1 g/ml), FK506 (0.1 g/ml), or rapamy-
cin (0.1 g/ml) were added to one group of cells. Non-activated cells and
CSA-treated non-activated cells were cultured for comparison. Cells
were cultured at 37 °C in a humidified atmosphere of 5% CO2 and
recovered at different times.
cDNA Synthesis and RDA—Cells were collected at 4 and 24 h Quick-
Prep® micro mRNA purification kit (Amersham Biosciences) according
to the manufacturer’s instructions. Double-stranded cDNA was ob-
tained with the Superscript Choice system for cDNA synthesis (Invitro-
gen). Testers were prepared from 3 g of mRNA of ConA-activated
CSA-treated T cells obtained after 4- and 24-h cultures. The driver was
prepared from 3 g of mRNA of ConA-activated T cells (4 and 24 h) and
non-activated spleen cells. RDA was performed as described previously
(17, 18). After three cycles of subtraction and amplification, subtraction
products were digested by DpnII and cloned into the BamHI site of
pUC18 plasmid. The cloned cDNA fragments were sequenced with
M13–20 primer using the ABI PRISM® BigDye™ terminator cycle
sequencing kit (PerkinElmer Life Sciences) and then processed on a
3700 DNA analyzer (Applied Biosystems). The nucleotide sequences
were analyzed using the BLASTN program and the NCBI GenBankTM
data base.
Analysis of the CSTAD Clone—The 5 end of the CSTAD cDNA clone
was obtained by rapid amplification of cDNA ends using the GeneRacer
kit (Invitrogen). The cDNA was prepared according to the manufactur-
er’s instructions using total RNA of ConA-activated CSA-treated thy-
mocytes. The PCR was performed with gene-specific primers in combi-
nation with the supplied GeneRacer 5 primer. The rapid amplification
of cDNA ends product was gel-purified, cloned with TOPO TA cloning
kit (Invitrogen) and then sequenced. The 3 end of the cDNA was
determined by homology analysis using the GenBank™ data base. The
complete sequence of the CSTAD clone was confirmed by sequencing
the UUGC1M0246K22F genomic clone obtained from Dr. D. Dunn
(University of Utah Genome Center, Salt Lake City, UT). Genomic
organization was determined by analysis of nucleotide sequences in the
mouse genome data base.
RT-PCR Analysis—Total RNA was isolated from various tissues, pu-
rified T cells were isolated by the acid guanidinium method (19), and
cDNA was synthesized with Moloney murine leukemia virus reverse
transcriptase (Invitrogen) according to the manufacturer’s protocol using
random hexanucleotide primers. The PCR primers are: -actin, 5-CAC-
GATTTCCCTCTCAGC and 5-GCACCACACCTTCTACAA; IL-2, 5-TG-
CTGACTCATCATCGA and 5-AGGATGGAGAATTACAG; synaptotag-
mine-2-like, 5-GGGTCATTTTAGCCAAAGC and 5-CAAACAAAACCC-
AAACAAA; -E-integrin, 5- TGCAGTTCATGACCAGGACA and 5-AG-
CTGACCACCAACATCTCCC; EDG-1, 5-CTGCTGGGCCCCTCTCTTCA
and 5-CGGCGCATCTCCTTGTTGGT; CSTAD-L, 5-ATGGGCACGCTT-
GTGTCA; CSTAD-C, 5-TGAGCCAGGTCACCCAAGAGATG; CSTAD-S,
5-GCCCGGAGAAACTGCTGAGAT.
PCR was performed for 30–40 cycles (95 °C, 30 s; 55 °C, 30 s; 72 °C,
30 s). After electrophoresis on a 1.5% agarose gel the PCR products were
visualized using a Vilber Lourmet transilluminator and the Biocapt
program.
Real-time PCR to Monitor Gene Expression—The differentially ex-
pressed genes were analyzed by real-time PCR using the above-men-
tioned primers. Total RNA was isolated, and cDNA was synthesized as
described above. Real-time PCR was conducted with a SYBR green kit
(PE Biosystems, Warrington, UK) according to the manufacturer’s spec-
ifications using 3 mM MgCl2 and 50 pmol of primer per reaction. The
amount of each gene was normalized to a housekeeping gene (-actin).
Plasmids, Transfections, and Fluorescence Microscopy—Plasmid con-
structs of full-length CSTAD-short and CSTAD-long fused to green
fluorescent protein (GFP) cDNA were generated by cloning PCR
products of the CSTAD genes in-frame with GFP into pcDNA3.1/
CT-GFP-TOPO (Invitrogen) according to the manufacturer’s instruc-
tions. Human fibrosarcoma 11.1 (U1A) cells were grown in Dulbecco’s
modified Eagle’s medium containing 2 mM L-glutamine, 50 g/ml strep-
tomycin, 50 units/ml penicillin, pyruvate, and 10% heat-inactivated
fetal calf serum. Cells were plated at 5  104 on glass coverslips in
24-well plates 16 h before transient transfection. Transient transfec-
tions using 2 g of plasmid per well were performed by calcium phos-
phate (125 mM). GFP fluorescence was monitored 24 h after transfec-
tion. Mitochondrial localization was assessed by fluorescence
microscopy using MitoTracker or monoclonal antibodies against mouse
cytochrome c or hsp-60. MitoTracker was added at 100 nM before cell
fixation, and cells were incubated for 10 min at 37 °C. Cells were then
fixed with 4% formaldehyde for 10 min at room temperature. Fixed cells
that had not been treated with MitoTracker were incubated with anti-
cytochrome c or anti-Hsp monoclonal antibodies and revealed with
Texas Red-coupled anti-mouse IgG1 antibodies. For cytochrome c de-
tection, permeabilization was carried out using 0.05% saponin as pre-
viously described (20). For HSP-60 detection, cells were permeabilized
with 0.1% SDS as described (20). Coverslips were mounted onto glass
slides using Mowiol mounting medium and 2.5% DABCO (1,4-
diazabicyclo(2.2.2.)octane). Confocal microscopy analysis was carried
out using a Zeiss LSM-510 microscope and software. Z-series optical
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sections were performed at 0.5-m increments. Green and red fluores-
cence emissions were collected separately to avoid fluorescence passage
from one channel to the other.
Cytofluorimetry Analysis of Mitochondrial Transmembrane Potential
and Cytochrome c Release—To measure changes in transmembrane
potential (), 11.1 (U1A) cells were first transfected with the C-
terminal GFP constructs of CSTAD-S and CSTAD-L. Twenty-four
hours after transfection the cells were loaded with 150 nM tetrameth-
ylrhodamine ethyl ester in phosphate-buffered saline, 1% bovine serum
albumin for 15 min at 37 °C. After the loading period the cells were
rinsed with phosphate-buffered saline/bovine serum albumin and re-
suspended in 15 nM tetramethylrhodamine ethyl ester in phosphate-
buffered saline/bovine serum albumin at room temperature. The  of
cells was measured by cytofluorimetry (FL3), and GFP-positive cells
were identified simultaneously on FL1. As a positive control for mem-
brane depolarization, cells were incubated with 1 M staurosporine
overnight.
Cytochrome c release was determined by cytofluorimetry using an-
tibodies against cytochrome c, as previously described (21). Cell death
was measured by cytofluorimetry after double-staining cells with pro-
pidium iodide and annexin V (22); both adherent cells and cells in
suspension were collected for analysis.
Subcellular Fractionation—The cells used in these studies, 293 T
cells, are derived from a human renal epithelial cell line that was
transfected by an adenovirus E1A gene product. The cells were grown in
Dulbecco’s modified Eagle’s medium containing 2 mM L-glutamine, 50
g/ml streptomycin, 50 units/ml penicillin, 1 mM pyruvate, and 10%
heat-inactivated fetal calf serum. Cells were plated at a density of 2 
106 cells/10-cm dish the day before transfection. The cells were tran-
siently transfected with 15 g of plasmid per dish using calcium phos-
phate. Two days after transfection the cells were collected, resuspended
in isotonic mitochondrial buffer (MB: 250 mM sucrose, 10 mM HEPES,
10 mM KCl, 2 mM MgCl2, 1 mM EGTA, pH 7.4), and lysed by 30–40
strokes with a Dounce homogenizer. The homogenate was centrifuged
at 1000 g for 5 min at 4 °C to eliminate nuclei and unbroken cells. The
supernatant was divided into nine aliquots and centrifuged at 10,000 
g for 15 min at 4 °C to obtain mitochondria-enriched pellets. The pellets
were resuspended in MB supplemented with or without 1% Triton
X-100 and treated with proteinase K (1–10 g/ml) on ice for 30 min.
After boiling for 10 min in the presence of SDS loading buffer, the
reaction mixtures were analyzed by SDS-PAGE and Western blotting.
Western Blot Analyses—The mitochondrial fractions were used for
detection of VDAC, CSTAD-GFP fusion protein, and cytochrome c. The
samples were separated by SDS-PAGE and transferred to nitrocellulose
membranes, which were blocked with 3% nonfat milk in Tris-buffered
saline containing 0.2% Tween 20 for 1 h at 37 °C. Blots were immuno-
stained with rabbit anti-VDAC polyclonal antibodies (Oncogene Re-
search Products, San Diego, CA) at a 1:2,000 dilution, rabbit anti-GFP
polyclonal antibodies (Oncogene) at 1:2,000 dilution, and mouse anti-
cytochrome c monoclonal antibody (Pharmingen) at 1:500 dilution at
4 °C overnight and probed with a 1:10,000 dilution of goat anti-rabbit
IgG or goat anti-mouse IgG antibodies coupled to horseradish peroxi-
dase. Specific bands were visualized by enhanced chemiluminescence
(PerkinElmer Life Sciences).
RESULTS
CSA Treatment Alters the Transcription of Genes in Acti-
vated T Cells—Two RDAs were performed on T cells activated
for 4 and 24 h by ConA in the presence or absence of CSA, as
described under “Materials and Methods.” Fifty clones from
each RDA were sequenced; readable nucleotide sequences were
obtained for 30 and 23 clones for the 4-h and the 24-h incuba-
tions, respectively, and the sequences were analyzed using the
BLASTN program and the GenBankTM data base. Primers
specific for the clones obtained were designed using the Oligo®
program (NBI). The effect of CSA on the level of expression of
these genes was tested by RT-PCR on splenic T cells activated
with ConA for 4 and 24 h in the presence or absence of CSA.
Non-activated cells and cells cultured in the presence of CSA
alone served as controls. Fig. 1 shows the level of mRNA accu-
mulation for the four genes whose expression had been altered
by the immunosuppressor, as detected by RDA. As expected,
induction of the IL-2 gene was prevented by the immunosup-
pressor (10), attesting to the effectiveness of the CSA treat-
ment. Incubation of cells with CSA alone had no effect on IL-2
gene expression but strongly increased the accumulation of
mRNA encoding EDG-1 and -E-integrin (Fig. 1).
Expression of the synaptotagmin-2-like gene was barely de-
tected in resting T cells, and its level was barely modified by T
cell activation. In contrast, gene expression was up-regulated
when activation was carried out in the presence of CSA (Fig. 1).
The mRNA encoding the gene that we have named CSA-con-
ditional, T cell activation-dependent (CSTAD) was detected in
non-activated T cells, but activation did not modify its amount.
However, activation in the presence of CSA resulted in a large
increase in the mRNA levels (Fig. 1). We, therefore, focused
subsequently on the characterization of the products of this
gene.
Genomic Localization and Tissue Distribution of CSTAD—
Rapid amplification of cDNA ends was performed to obtain the
complete sequence of the CSTAD cDNA, revealing a sequence
of 901 nucleotides. Alignment analyses with the GenBankTM
data base showed that the CSTAD cDNA shares 785 nucleo-
tides at the 3 end with a Riken cDNA clone of 816 bases
encoding a gene with unknown function located on mouse chro-
mosome 2 (GenBankTM accession number AK020589; Gene ID,
ENSMUSESTG00000040463). However, the two cDNAs differ
in their 5 end region by a stretch of 31 nucleotides, which are
unique to the Riken clone, and by a sequence of 116 bases that
are present exclusively in the CSTAD cDNA. The localization
of the CSTAD cDNAs was determined from GenBankTM data
base analysis (Fig. 2A).
Two exons had been defined in the Riken clone. The coding
sequences and the translation products are represented in Fig.
2B. The Riken and CSTAD cDNAs, thus, represent two alter-
native splice variants of the CSTAD gene. We named them
CSTAD-S (identified by Riken) for the short and CSTAD-L
(identified by RDA) for the long isoform, respectively. These
FIG. 1. T cell activation in the presence of CSA results in gene
up-regulation. Non-activated spleen cells (NA) or spleen cells acti-
vated with ConA in the absence (ConA) or presence of CSA
(ConACSA) were cultured for 4 and 24 h. A group of cells was incu-
bated with CSA alone (CSA). After T cell purification and RNA extrac-
tion, PCR was performed with primers specific for IL-2, -E-integrin
(-E-Int), EDG-1, synaptotagmin-2-like, and CSTAD (CSTAD-L and
CSTAD-C), described under “Materials and Methods.” The amplified
material was resolved by gel electrophoresis, and the images were
collected using a Vilber Lourmet transilluminator. -Actin served as an
internal standard for the quality and quantity of the mRNA prepara-
tion. The data are representative of five independent experiments.
Mitochondrial Protein Induced by Cyclosporin A10558
 at U
niv of the Pacific on A
pril 17, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
cDNA encode two proteins of 104 (CSTADp-S) and 141 amino
acids (CSTADp-L).
Up-regulation of the CSTAD gene could change the expres-
sion level of both the long and short CSTAD forms. This was
assessed by PCR using the specific primers shown in Fig. 2A.
Both CSTAD-L and CSTAD-S mRNAs increased in T cells
activated for 4 and 24 h in the presence of CSA (Fig. 3A).
Real-time PCR was used to quantify the amount of both
mRNAs (Fig. 3B). The data are presented as the ratio of the
amount of CSTAD-L and -S in T cells activated in the presence
of CSA to the amount of mRNA for the other experimental
groups. The ratio of CSTAD-L and -S in CSA-treated cells
versus non-activated cells is also shown. Both the CSTAD-L
and CSTAD-S isoforms increased by a factor of 4–5 at 4 h
compared with T cells activated by ConA. Similar increases
were found for the other conditions (Fig. 3). At 24 h CSTAD
increased by a factor of 10–13 compared with ConA-activated T
cells. However, the absolute amount of the CSTAD isoforms
decreased at 24 h (Fig. 3, panel A).
We next investigated the tissue distribution of the two alter-
native splice variants of CSTAD. All tissues tested positive for
the two alternative splice variants, but the relative expression
of the isoforms varied considerably. CSTAD-L is abundant in
the intestines, thymus, and skin (Fig. 4), whereas CSTAD-S is
highly represented in the skin but is less abundant in the
thymus and is barely detectable in the intestines.
CSA Treatment during Immunization Increases the Expres-
sion of CSTAD in Mice—Because a polyclonal activator induced
CSTAD overexpression in vitro, we next evaluated whether
CSTAD expression may change during physiological conditions
in vivo. For this purpose we used transgenic mice expressing a
T cell receptor specific for the pigeon cytochrome c peptide (16),
whose immunization with the pigeon cytochrome c peptide
leads to the expression of a number of cytokine-encoding genes
(23). The mice were treated with CSA 1 day before and on the
day of immunization, as previously described (23). As shown in
Fig. 5, the efficiency of CSA-induced immunosuppression is
attested by the blockade of the IL-2 gene. Expression of
CSTAD-L and CSTAD-S was measured in mice treated with
CSA alone or after immunization with the pigeon cytochrome c
peptide with or without CSA. Mice were sacrificed 6 h after
immunization, and the T cells were purified. The level of ex-
pression of the two CSTAD isoforms is shown in Fig. 5. Al-
though the two alternative splice variants were detected in
untreated or immunized mice, they were both up-regulated
after immunization in the presence of CSA. This demonstrates
FIG. 2. Organization of the CSTAD
gene. A, organization of the CSTAD gene
as derived from the alignment of the se-
quences of the CSTAD and Riken
(AK020589) clones with the mouse Gen-
BankTM data base. The position of the
primers used for the amplification of the
CSTAD-L and -S isoforms is indicated by
the arrows. B, unique and shared nucleo-
tide and amino acid sequences of the
short and long isoforms. The specific
primer sequences are underlined.
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that CSTAD gene transcription in T cells activated in the
presence of the immunosuppressor may be physiologically
relevant.
Blockade of the Calcineurin Activation Pathway Increases
CSTAD Expression—Two other immunosuppressors, FK506
and rapamycin, were used to ascertain whether the up-regula-
tion of the CSTAD gene is linked to the inhibition of the
calcineurin pathway. FK506, like CSA, acts on calcineurin,
whereas rapamycin interferes with activation due to IL-2 bind-
ing to its high affinity receptor (for review, see Refs. 24 and 25).
Splenic T cells were activated for 4 h in the presence or absence
of CSA, FK506, or rapamycin. Control cells received the immu-
nosuppressors but without activation. At the end of the stim-
ulation, RT-PCR was carried out using CSTAD-L- and CSTAD-
S-specific primers. As shown in Fig. 6, the IL-2 gene encoding
mRNA was induced in T cells activated by ConA in the pres-
ence or absence of rapamycin but not in the presence of CSA or
FK506, demonstrating the specificity of the immunosuppres-
sion. mRNA encoding for CSTAD-S and CSTAD-L accumulated
in large amounts when activation was carried out in the pres-
ence of CSA or FK506. In contrast, rapamycin had no effect,
strongly suggesting that the blockade of the calcineurin path-
way is involved in up-regulation of the CSTAD gene.
CSTAD-S and CSTAD-L Colocalize with Mitochondrial
Markers—To identify the cellular localization of the CSTAD
gene products, the cDNAs corresponding to the two isoforms
were fused with the GFP gene. N-terminal and C-terminal GFP
constructs were made. After transient transfection in mouse
3T3 fibroblasts, only the C-terminal construct gave a reproduc-
ible, high level of expression of the fused genes. Twenty-four
hours after transient transfection the cells were analyzed by
confocal microscopy. Both long and short CSTAD proteins were
found in discrete subcellular organelles that morphologically
resemble mitochondria (results not shown). To avoid competi-
tion with endogenous CSTAD proteins, a human fibroblast cell
line, 11.1 (U1A), was then used to confirm mitochondrial local-
ization, since an orthologous CSTAD gene was not found in the
human genome. When mitochondria were labeled with Mito-
Tracker, which accumulates in active mitochondria, or antibod-
ies against cytochrome c or hsp-60, the CSTAD-GFP proteins
were found to co-localize with the three mitochondrial markers
(Fig. 7). However, better co-localization was observed between
CSTAD-GFP and MitoTracker or hsp-60 (Fig. 7, A, B, D, and E)
than with cytochrome c (Fig. 7, C and F).
CSTAD-S and CSTAD-L Are Localized to the Outer Mem-
brane of Mitochondria—To determine the mitochondrial local-
ization of CSTAD-S and CSTAD-L, we transiently transfected
293T cells with the plasmids encoding these isoforms fused to
GFP. Subcellular fractions enriched in mitochondria were iso-
lated by differential centrifugation (26) and treated with in-
creasing concentrations of proteinase K as described under
“Materials and Methods.” As shown in Fig. 8 (a typical exper-
iment of three), the bands immunostained with the anti-GFP
antibodies are degraded at 10 g/ml proteinase K, whereas in
the Triton X-100-solubilized mitochondria the CSTAD-GFP fu-
sion proteins are fully digested at 5 g/ml. Interestingly, the
VDAC2 and VDAC1 proteins, which reside on the outer mem-
brane of the mitochondria, are also degraded in the same range
FIG. 3. Estimation of CSTAD-L and CSTAD-S mRNA accumu-
lation by real-time PCR. A, cells activated in the presence or absence
of CSA, as described in the legend of Fig. 1, were collected at 4 and 24 h.
After T cell purification RNA was prepared, and PCR was performed
with primers specific for CSTAD-L and CSTAD-S cDNA, as described
under “Material and Methods.” Gels and analyses were performed as
indicated in the legend of Fig. 1. The data are representative of four
independent experiments. B, real-time PCR using primers specific for
each CSTAD isoform was performed as described under “Material and
Methods” on the experimental groups described above. The results are
expressed as fold increase of the CSTAD-L and -S isoforms in non-
activated (NA) or activated T cells (ConA) or in T cells activated in the
presence of CSA (ConACSA) or in T cells cultured in the presence of
CSA (CSA). The data are representative of three independent
experiments.
FIG. 4. Tissue distribution of the CSTAD-L and -S isoforms.
RNA was prepared from different tissues as described under “Materials
and Methods.” PCR was performed using primers specific for the long
and short isoforms. The amplified material was resolved by gel electro-
phoresis, and the images were collected using a Vilber Lourmet
transilluminator. The data are representative of three independent
experiments. -Actin served as an internal standard for the quality and
quantity of the mRNA preparation.
FIG. 5. The CSTAD gene is up-regulated in immunosup-
pressed, immunized mice. A group of transgenic mice expressing a T
cell receptor specific for the cytochrome c peptide (88–104) was immu-
nized with the cytochrome c peptide alone (Peptide) or with CSA (Pep-
tide  CSA). Non-immunized (NI) and CSA-treated (CSA) mice were
used as controls. Spleen were collected 6 h after peptide administration,
and RT-PCR for each isoform was performed as described in the legend
of Fig. 1. The data are representative of three experiments.
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of proteinase K concentrations as the CSTAD proteins. Con-
versely, cytochrome c, which is a marker for the intramem-
brane space, is not cleaved by the protease, except when the
mitochondria are solubilized in detergent (Fig. 8). Thus, these
experiments strongly suggest that the CSTAD proteins are
localized on the outer membrane of mitochondria.
CSTAD-S and CSTAD-L Depolarize the Mitochondrial Mem-
brane Potential—After a 24-h transfection with the GFP con-
structs of CSTAD-S and CSTAD-L both isoforms were shown to
decrease the transmembrane potential () across the mito-
chondrial inner membrane (Fig. 9), although CSTAD-S was
more effective than CSTAD-L. Among cells expressing GFP,
more than half of the cells transfected with CSTAD-S had
depolarized membranes compared with almost one-fifth for
cells transfected with CSTAD-L.
Mitochondrial membrane polarization often leads to cyto-
chrome c release from mitochondria. However, neither the
short nor the long isoform led to release of cytochrome c into the
cytosol (data not shown). Consistent with these results, we also
observed that overexpression of either isoform does not lead to
cell death of transfected cells. Neither apoptosis (as measured
by annexin V labeling) nor necrosis (assayed by propidium
iodide labeling) was observed in transfected cells (data not
shown).
DISCUSSION
We have previously reported that activation of T cells in the
presence of CSA induces the synthesis of a large number of
proteins (15). However, the proteomic analysis of the newly
synthesized polypeptides did not permit their characterization,
an essential step in understanding the mechanisms underlying
the deleterious effects associated with CSA therapy. Use of the
RDA technique allowed us to identify genes that are modulated
in activated T cells by the immunosuppressor either negatively
or positively. Among these genes we have presently focused on
the CSA-conditional, T cell activation-dependent gene, CSTAD.
The CSTAD cDNA obtained in the present study is 901
nucleotides long. It possesses an open reading frame beginning
with an ATG at position 1, a stop codon at position 426, and a
potential polyadenylation site at position 880. This cDNA
shares 784 nucleotides with a Riken cDNA clone belonging to a
gene of unknown function(s) located on mouse chromosome 2
(Ref. 27, accession number AK020589). The RDA and the Riken
clones were named CSTAD-L and -S for the long and short
isoform, respectively. They share a common sequence of 784
nucleotides located in the 3 region and differ in their 5 region
by a sequence of 116 nucleotides, which is unique to CSTAD-L,
and by a sequence of 31 nucleotides, which is found exclusively
in CSTAD-S. The CSTAD-S cDNA is encoded by two exons
separated by an intron of 13,084 bases (gene ID ENSMUS-
ESTG00000040463). The 116 nucleotides that are unique to
the CSTAD-L cDNA are located immediately upstream of the
CSTAD-S second exon and are, thus, situated in this interven-
ing sequence. A third alternative splice variant was predicted
in the project Ensembl (www.ensembl.org) from the gene struc-
ture using a combination of calculations (Exonerate, Blast, and
Est-Genome). PCR amplification using primers located in exon
1 and exon 2 of this presumed cDNA did not produce any
amplified material from resting, activated, or activated and
immunosuppressed T cells, thus excluding the existence of
such an isoform in these cells. From our present data and the
structure of the Riken cDNA clone we propose the organiza-
tion of the CSTAD gene illustrated in Fig. 2. The “Riken” or
CSTAD-S variant originates from the splicing and joining of
FIG. 6. Accumulation of mRNA encoding the long and short
CSTAD isoforms depends on the blockade of the calcineurin
pathway. Spleen cells were activated with ConA either alone (ConA) or
in the presence of CSA (ConACSA), FK506 (ConAFK506), or rapa-
mycin (ConARAPA). Non-activated cells were cultured with CSA
(CSA), FK506 (FK506), or rapamycin (RAPA). Four hours after activa-
tion the cells were recovered, and T cells were purified. RT-PCR was
performed using primers specific for the short and long isoforms, and
the amplified material was analyzed as described in the legend of
Fig. 1.
FIG. 7. Mitochondrial localization of CSTAD-L and CSTAD-S
GFP-fused proteins. Human fibroblasts were transfected with a plas-
mid encoding either the long (upper panels) or short (lower panels)
CSTAD isoform linked to the GFP gene. Twenty four hours later cells
were fixed, and mitochondria were stained using MitoTracker (MITO, A
and D), anti-hsp-60 (B and E), or anti-cytochrome c (Cyt c) monoclonal
antibodies (C and F) followed by confocal microscopy analysis, as de-
scribed under “Material and Methods.” A medial confocal optical section
is shown. Left column, CSTAD-L-GFP or CSTAD-S-GFP (green); center
column, MitoTracker, cytochrome c or hsp-60 labeling (red); right col-
umn, overlay of green and red fluorescence.
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exon 1 and 2B, whereas the CSTAD-L variant derives from the
direct transcription of the sequence encoding exon 2A and 2B.
CSTAD encodes two proteins of 104 and 141 amino acids. The
corresponding sequences do not share obvious homology with
other proteins in the data bank and do not contain potential
glycosylation or phosphorylation sites.
The CSTAD gene is localized on mouse chromosome 2 (2A3)
between the growth factor-independent 1B (gfi-1B) and the
carboxyl ester lipase (cel) genes. These genes (Gfi-1B and Cel)
have orthologues on human chromosome 9 (9q34.13 and
9q34.3). However, an orthologue of CSTAD was not found in
the human gene bank data base. In addition, PCRs using the
murine CSTAD-S and CSTAD-L primers did not yield ampli-
fied material on cDNA from Jurkat cells (data not shown),
suggesting that CSTAD has no counterpart in humans; never-
theless, the presence of a functional homologue of CSTAD in
humans cannot be excluded.
Up-regulation of CSTAD, as measured by the real-time PCR
of the short and long form, is of the order of 5–12-fold in T cells
activated in the presence of CSA compared with ConA-acti-
vated or non-activated T cells. This increased mRNA accumu-
lation is observed 4 and 24 h after activation, although the
relative amount of the mRNAs is larger at 4 h than at 24. No
major differences in the relative quantity of the long and short
isoforms were detected, suggesting that activation in the pres-
ence of CSA does not alter the mechanism(s) involved in the
maturation of CSTAD mRNA precursors. However, the expres-
sion of the two alternative splice variants may be differentially
regulated, as illustrated by the differences in the levels of
CSTAD-L and CSTAD-S mRNA in different tissues. Both iso-
forms are detected in all the organs tested, and although
CSTAD-L and -S are highly represented in the skin, the long
isoform is predominantly abundant in the intestine and the
thymus, whereas the short form is expressed at higher levels in
brain and kidney. It is interesting to note a correlation between
the high level of CSTAD-L mRNA accumulation and the rapid
cell turnover of the cells in skin, thymus, and intestine.
CSTAD up-regulation is also observed in mice immunized in
the presence of CSA. A low level of CSTAD mRNA accumula-
tion is found in splenic T cells of naive or peptide-immunized
mice. CSA treatment alone had no effect on the relative abun-
dance of the two alternative splice variants. Immunization in
the presence of CSA resulted in a substantial increase of both
isoforms. One may, therefore, conclude that CSTAD gene up-
regulation by the immunosuppressor is of physiological rele-
vance in mice.
The inhibition of calcineurin activity by the CSA-cyclophilin
complexes has been well characterized. The inhibition prevents
the dephosphorylation of NFAT, precluding its migration to the
nucleus, a mandatory step for the transcription of growth and
differentiation genes necessary for the proper effector function
of T cells (7, 28). FK506, another immunosuppressor, also in-
FIG. 8. CSTAD-S and CSTAD-L iso-
forms reside on the outer membrane
of mitochondria. Mitochondrial prepa-
rations from 293 T cells transiently trans-
fected with CSTAD-S or CSTAD-L were
treated with various concentrations of
proteinase K in the absence () or pres-
ence () of Triton X-100 at 4 °C for 30
min. The samples were analyzed by West-
ern blot with rabbit anti-GFP polyclonal
antibodies (upper panels), rabbit anti-
VDAC polyclonal antibodies (middle pan-
els), and mouse anti-cytochrome c (Cyt c)
monoclonal antibody (lower panels).
FIG. 9. Overexpression of CSTAD
leads to depolarization of the mito-
chondrial transmembrane potential.
Cells were transfected with a construct
encoding GFP alone (A) or the short (C)
and long (D) isoforms of CSTAD co-ex-
pressing GFP. As a control (B), untrans-
fected cells were treated with staurospo-
rine. The transmembrane potential ()
was measured using tetramethylrhodam-
ine ethyl ester, which accumulates in ac-
tive mitochondria but not in depolarized
mitochondria. By cytofluorimetry, both
transfected (GFP-expressing) cells and
 were measured simultaneously. The
numbers in each quadrant refer to the
percentage of cells in each quadrant.
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hibits calcineurin, and activation in its presence also induces
CSTAD gene up-regulation. In contrast, rapamycin, which in-
terferes with a late signal originating from the occupancy of the
IL-2 receptor, does not induce CSTAD overexpression. Taken
together, these data show that inhibition of calcineurin in
activated T cells up-regulates CSTAD gene expression, sug-
gesting that, depending on its activation/inactivation status,
this enzyme could be involved both in positive and negative
control of gene expression. Even though activation is required
for CSA to modify the expression of the CSTAD gene in vitro or
in vivo, CSA by itself up-regulates -E-integrin and EDG-1
gene transcription (Fig. 1). Similar CSA-induced gene up-reg-
ulation was also reported for IL-6 and transforming growth
factor- in a variety of cells (29–31). Whether the up-regulation
of these genes is independent from the activation of a non-
classical calcineurin pathway remains to be determined.
The mechanisms of protein import into the different mito-
chondrial compartments (the inner or outer membrane, the
intermembrane space, or matrix) are being investigated exten-
sively by a number of laboratories, which has led to the iden-
tification of targeting signals located in the N-terminal end of
mitochondrial-located proteins (for review, see Ref. 32). How-
ever, none of the targeting signals described until now has been
found in either the long or short forms of CSTAD. Internal
signals have also been described (33, 34), but these are also
absent from both CSTAD isoforms. Nevertheless, many mito-
chondrial import signals still remain to be identified, and it is
still possible that a heretofore uncharacterized signal may be
responsible for targeting of CSTAD to mitochondria.
cDNAs encoding CSTAD fused to GFP were transfected in a
human cell line, and their localization was analyzed by confocal
microscopy. A human cell line was chosen for most of the
localization studies since CSTAD is not found in humans, ex-
cluding interference between transfected CSTAD and an or-
thologous protein. Both CSTAD isoforms were sorted predom-
inantly to mitochondria, as the corresponding GFP-tagged
proteins co-localized with the mitochondrial markers Mito-
Tracker, cytochrome c, and hsp-60. Both CSTAD-S and
CSTAD-L isoforms reside on the outer membrane of mitochon-
dria, since they are cleaved by proteinase K. As a positive
control, VDAC proteins, which are known to be expressed on
the surface of this organelle, is also degraded by the protease
(Fig. 8).
Interestingly, more than 50% of the cells transfected with the
short isoform show a depolarization of the inner mitochondrial
membrane, whereas this is the case of only 20% of the cells
transfected with the long isoform. In both groups the depolar-
ization was not accompanied by the release of cytochrome c,
excluding an apoptotic effect of the CSTAD proteins. Finally,
no apoptosis nor necrosis of transfected cells was observed.
Calcineurin, in addition to NFAT, also dephosphorylates and
activates BAD (35), a pro-apoptotic member of a family of
proteins anchored to the outer membrane of the mitochondria.
This process is blocked by CSA and FK506. CSA also inhibits
apoptosis through its binding to cyclophilin D, a mitochondrial
protein located exclusively in the matrix (36, 37) and involved
in the mitochondrial permeability transition (38, 39). Thus, the
inhibition by CSA of calcineurin and its binding to cyclophilin
D, although acting at different levels of cell physiology, prevent
or retard cell apoptosis. CSTAD, a gene induced by CSA during
T cell activation, produces two proteins that localize to mito-
chondria and provoke membrane depolarization, but consistent
with the anti-apoptotic properties of CSA acting at other levels,
CSTAD-induced mitochondrial membrane depolarization does
not lead to apoptosis. This finding reveals the presence of a new
mitochondria-dependent signaling pathway stimulated by CSA
treatment.
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